Journal ArticleDOI
Tumour microenvironment-responsive nanoplatform based on biodegradable liposome-coated hollow MnO2 for synergistically enhanced chemotherapy and photodynamic therapy.
Xiangtian Deng,Xiangtian Deng,Qingcheng Song,Yiran Zhang,Yiran Zhang,Weijian Liu,Hongzhi Hu,Yingze Zhang,Yingze Zhang +8 more
Reads0
Chats0
TLDR
In this paper, hollow manganese dioxide nanoparticles (HMDNs) loaded with the hydrophilic chemotherapeutic drug (acriflavine, ACF) were further encapsulated by pH-sensitive liposome to form core-shell nanocomposite, with surface modified with arginine-glycine-aspartic acid (RGD) peptide to achieve tumour targeting.Abstract:
BACKGROUND Existing therapeutic efficacy of chemotherapy and photodynamic therapy (PDT) is always affected by some resistance factors from tumour environment (TME), such as hypoxia and the antioxidant defense system. PURPOSE This study aims at developing a cascaded intelligent multifunctional nanoplatforms to modulate the TME resistance for synergistically enhanced chemo- and photodynamic therapies. METHODS In this study, we synthesised hollow manganese dioxide nanoparticles (HMDNs) loaded with the hydrophilic chemotherapeutic drug (acriflavine, ACF) and the hydrophobic photosensitizer (chlorine6, Ce6), which was further encapsulated by pH-sensitive liposome to form core-shell nanocomposite, with surface modified with arginine-glycine-aspartic acid (RGD) peptide to achieve tumour targeting. RESULTS After uptake by tumour cells, the liposome shell was rapidly degraded by the low pH, and the inner core could be released from the liposome. Then, the released HMDNs/ACF/Ce6 would be dissociated by low pH and high levels of intracellular GSH within TME to release encapsulated drugs, thereby resulting in synergistic effects of chemotherapy and PDT. Meanwhile, the released ACF could bind with HIF-1a and then inhibit the expression levels of HIF-1's downstream signalling molecules P-gp and VEGF, which could further strengthen the antitumor effects. As a result, HMDNs/ACF/Ce6@Lipo-RGD NPs with laser irradiation exhibited superior anti-tumour therapeutic efficiency.read more
Citations
More filters
Journal ArticleDOI
Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer
Mohamed Haider,Amr Elsherbeny,Valeria Pittalà,Valeria Consoli,Maha Ali Alghamdi,Zahid Hussain,Ghalia Khoder,Khaled Greish +7 more
TL;DR: A broad framework for understanding the different molecular mechanisms of DR in lung cancer is provided, and novel nanomedicine therapeutics aimed at improving the efficacy of treatment of various forms of resistant LC are presented.
Journal ArticleDOI
Advances in Liposome-Encapsulated Phthalocyanines for Photodynamic Therapy
TL;DR: The current status in the development of liposome-based systems for the targeted delivery of phthalocyanines for photodynamic therapy (PDT) is described in this paper .
Journal ArticleDOI
Aptamer-mediated hollow MnO2 for targeting the delivery of sorafenib
Ziyu Wang,Cuicui Wu,Jinren Liu,Junli Yu,Qiangqiamg Yin,Hongda Tian,Zhipeng Ding,Guiqiang Qi,Li Wang,Liguo Hao +9 more
TL;DR: The hollow mesoporous MnO2 (H-MnO2) nanoparticles equipped with target substance aptamers (APT) on the surface were used to load SRF for the first time as mentioned in this paper .
Journal ArticleDOI
Advances of MnO2 nanomaterials as novel agonists for the development of cGAS-STING-mediated therapeutics
Tangxin Zhang,Chunmiao Hu,Wenting Zhang,Yongdui Ruan,Yuhe Ma,Dongsheng Chen,Yuh-Lin Huang,Shuhao Fan,Wen-Jong Lin,Yifan Huang,Kangsheng Liao,Hong-e Lu,Jun Fa Xu,Jiang Pi,Xinrong Guo +14 more
TL;DR: In this paper , the authors introduced the methods for the preparation of MnO2 nanomaterials as well as their biological activities and discussed the detailed mechanisms of manganese ion (Mn2+) for cGAS activation by converting into Mn2+.
Journal ArticleDOI
Constructing new acid-activated anticancer peptide by attaching a desirable anionic binding partner peptide
TL;DR: In this article , a new acid-activated anticancer peptides (ACPs) was designed by conjugating a cationic ACP LK to its anionic binding partner peptide (LEH) via a disulphide linker.
References
More filters
Journal ArticleDOI
Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation
Panu Jaakkola,David R. Mole,Ya-Min Tian,Michael I. Wilson,Janine Gielbert,Simon J. Gaskell,Alex von Kriegsheim,Holger F. Hebestreit,Mridul Mukherji,Christopher J. Schofield,Patrick H. Maxwell,Christopher W. Pugh,Peter J. Ratcliffe +12 more
TL;DR: It is shown that the interaction between human pVHL and a specific domain of the HIF-1α subunit is regulated through hydroxylation of a proline residue by an enzyme the authors have termed Hif-α prolyl-hydroxylase (HIF-PH).
Journal ArticleDOI
Modulation of oxidative stress as an anticancer strategy.
TL;DR: The controversial role of ROS in tumour development and in responses to anticancer therapies is addressed, and the idea that targeting the antioxidant capacity of tumour cells can have a positive therapeutic impact is elaborate.
Journal Article
Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells
Ted P. Szatrowski,Carl Nathan +1 more
TL;DR: Constitutive generation of large amounts of reactive oxygen intermediates, if it occurs in vivo, might contribute to the ability of some tumors to mutate, inhibit antiproteases, injure local tissues, and therefore promote tumor heterogeneity, invasion, and metastasis.
Journal ArticleDOI
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
TL;DR: This review summarizes the current state of knowledge regarding the molecular mechanisms by which Hif-1 contributes to cancer progression, focusing on clinical data associating increased HIF-1 levels with patient mortality and pharmacological data showing anticancer effects of H IF-1 inhibitors in mouse models of human cancer.
Journal ArticleDOI
Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy
TL;DR: Clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.